Byrna Technologies Reports Record Results for Fiscal Fourth Quarter and Full Year 2024 February 7, 2025
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option February 7, 2025